First patient dosed in dry eye trial

A phase 1 clinical trial of Ocular Therapeutix’s dry eye treatment OTX-CSI is underway, with the first patient being dosed, the company announced.

The cyclosporine insert is a bioresorbable intracanalicular insert that releases cyclosporine over the ocular surface for up to 3 months.

The U.S.-based, open-label, single-center trial of five patients with dry eye disease will evaluate the safety and efficacy of the new treatment over 4 months.

“We believe that the intracanalicular route of administration could provide key benefits in all ocular surface diseases but particularly in dry eye,” Michael Goldstein, MD, MBA, chief medical officer, said in a press release. “The intracanalicular route allows for preservative-free delivery of a constant dose of cyclosporine, so it may be less irritating to the ocular surface than drop therapies.”

A phase 1 clinical trial of Ocular Therapeutix’s dry eye treatment OTX-CSI is underway, with the first patient being dosed, the company announced.

The cyclosporine insert is a bioresorbable intracanalicular insert that releases cyclosporine over the ocular surface for up to 3 months.

The U.S.-based, open-label, single-center trial of five patients with dry eye disease will evaluate the safety and efficacy of the new treatment over 4 months.

“We believe that the intracanalicular route of administration could provide key benefits in all ocular surface diseases but particularly in dry eye,” Michael Goldstein, MD, MBA, chief medical officer, said in a press release. “The intracanalicular route allows for preservative-free delivery of a constant dose of cyclosporine, so it may be less irritating to the ocular surface than drop therapies.”